PolyPid

Company Overview

Snapshot

Founded in February 2008, PolyPid operates with 51–200 employees and has raised a total of $239.24 million across 15 funding rounds from 8 investors. In June 2020, the company went public on NASDAQ.

Business overview

PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes through its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. This technology enables the precise, controlled, and prolonged local delivery of active pharmaceutical ingredients over durations ranging from days to months. The company's lead product candidate, D-PLEX100, is currently in a Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. Additionally, its OncoPLEX is in preclinical testing for the treatment of solid tumors, starting with glioblastomas. PolyPid operates within the Health Tech & Life Sciences sector, specifically in Drug Delivery, targeting the pharmaceutical and life sciences markets.

Strategic signal

In September 2025, PolyPid is scheduled to present its positive Phase 3 SHIELD II topline results at the American College of Surgeons Clinical Congress. This upcoming presentation of clinical trial data is a significant validation of the company's lead product candidate, D-PLEX100, and could be a pivotal moment for its commercialization prospects and market positioning in surgical infection prevention.

Company Intelligence Q&A

What is PolyPid's primary focus?

PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes through locally administered, controlled, prolonged-release therapeutics.

When did PolyPid go public?

PolyPid went public on NASDAQ in June 2020.

What is the status of PolyPid's lead product candidate, D-PLEX100?

D-PLEX100 is currently in a Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.

What is the latest funding event for PolyPid?

This was a private equity funding round.

What is the status of PolyPid's OncoPLEX program?

OncoPLEX is currently in preclinical stage testing for the treatment of solid tumors, beginning with glioblastomas.